AMARIN ACQUIRES PARKINSON'S DISEASE DRUG CANDIDATE

Amarin Corporation plc today announced the acquisition of global rights to a novel oral formulation of apomorphine for the treatment of "off" episodes in patients with advanced Parkinson's disease. The novel oral formulation provides rapid absorption of apomorphine directly into the bloodstream after sublingual (under the tongue) administration. This novel formulation would offer patients an improved alternative to the currently available injectable formulation of apomorphine.
Yahoo News